10-Q · May 14, 2026
Larimar Therapeutics reported a net loss of $29.6 million or $0.31 per share for Q1 2026, marking a slight improvement over a loss of $29.3 million or $0.46 per share in Q1 2025. Despite having no revenue, the company…
Earnings analysis · 10-Q
LRMR earnings analysis
Filed August 4, 2026 · Our reading of the company's report
The latest report
Larimar remains pre-revenue and reported a Q2 2026 net loss of $32.8 million, up from $26.2 million in Q2 2025, as operating expenses rose to $34.4 million. Per-share loss improved to $0.30 from $0.41 a year ago and…
Read full summary
Larimar remains pre-revenue and reported a Q2 2026 net loss of $32.8 million, up from $26.2 million in Q2 2025, as operating expenses rose to $34.4 million. Per-share loss improved to $0.30 from $0.41 a year ago and $0.31 sequentially, reflecting a larger share base following financing. The key positive is regulatory execution—rolling BLA submission began in June and Phase 3 first-patient dosing is planned for Q3 2026—but elevated cash burn, an explicit going-concern disclosure, safety-related attrition, and a Form 483 at a contract manufacturer remain material risks.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.3
What stood out
-
EPS loss narrowed year over year and sequentially
Diluted loss per share narrowed to $0.30 in Q2 2026 from a $0.41 loss in Q2 2025 and a $0.31 loss in Q1 2026, despite the quarterly net loss increasing to $32.8 million from $26.2 million a year earlier.
-
Rolling BLA has begun
The company initiated its rolling BLA in June 2026 and expects the remaining modules in 2H 2026. FDA feedback stated the existing package appears capable of supporting BLA submission and review, although approval remains subject to FDA review.
-
Equity raise strengthened liquidity
Cash, cash equivalents and marketable securities were $156.3 million at June 30, 2026, following $107.6 million of net proceeds from the February 2026 equity offering.
-
Open-label biomarker and clinical signal
In the open-label study, skin FXN exceeded asymptomatic-carrier levels in 82% (9 of 11) of participants at six months and 100% (9 of 9) at one year; management reported a 2.6-point mFARS benefit at one year.
-
Phase 3 initiation targeted for Q3
Management plans to dose the first patient in the global confirmatory Phase 3 study in Q3 2026, with sites planned across the U.S., EU, UK, Canada and Australia.
-
Pre-commercial company
No product revenue has been generated to date, consistent with Larimar's status as a clinical-stage biotechnology company.
What to watch
-
BLA acceptance and approval remain uncertain
The newly added risk factor states that FDA may not accept or approve the accelerated-approval BLA. The first BLA module was submitted in June 2026, while the remaining modules are only expected in the second half of 2026; FDA also said safety-database adequacy will be reviewed at submission.
-
Manufacturer inspection observations threaten timing
FDA issued a Form 483 to Larimar's third-party fill-and-finish manufacturer. Although the manufacturer has a remediation plan, the filing states it may not be timely or satisfactory to FDA and could cause a delay or warning letter.
-
Cash burn and going-concern disclosure
Operating cash use rose to $88.6 million in the first six months of 2026 from $45.9 million a year earlier. Despite $156.3 million of cash and marketable securities, management says these resources are not sufficient for at least one year from financial-statement issuance and conditions raise substantial doubt about going concern.
-
Anaphylaxis caused 10 discontinuations
Twenty-one of 43 open-label participants discontinued since January 2024, including 10 participants who experienced anaphylaxis. All 10 returned to their usual state of health after standard therapy, but the discontinuations constrain the safety dataset.
-
Development and commercialization costs rising
Q2 R&D expense increased $4.6 million to $28.0 million and G&A increased $1.9 million to $6.4 million, driving total operating expenses up $6.6 million year over year to $34.4 million.
Management's outlook
No numeric financial guidance was provided in the 10-Q. Management expects to submit the remaining rolling BLA modules in the second half of 2026 and plans first-patient dosing in the global confirmatory Phase 3 study in the third quarter of 2026; it expects cash resources to fund operations into Q3 2027.
Earlier filings 4
10-K · March 19, 2026
Larimar remains a clinical-stage biotech focused on nomlabofusp for Friedreich’s ataxia; the filing reports FDA Breakthrough Therapy Designation (Feb 2026), continued FDA alignment on using skin FXN as a reasonably…
10-K · March 14, 2024
Larimar is a clinical-stage biotech focused on nomlabofusp, a CPP‑delivered frataxin replacement for Friedreich’s ataxia. The company reported positive Phase 2 topline results (Feb 2024), has initiated a 25 mg daily OLE…
10-Q · August 11, 2022
Larimar reported a smaller Q2 2022 net loss and lower R&D spend versus Q2 2021, but liquidity declined materially and the FDA clinical hold on CTI‑1601 remains unresolved. Net loss for the three months ended June 30,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.